Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre,

Slides:

Advertisements

Similar presentations

Crohn's disease Prof Daniel C Baumgart, MD, Prof William J Sandborn, MD The Lancet Volume 380, Issue 9853, Pages (November 2012) DOI: /S (12)

Advertisements

Volume 387, Issue 10037, Pages (June 2016)

Volume 381, Issue 9862, Pages (January 2013)

Enhanced performance feedback and patient participation to improve hand hygiene compliance of health-care workers in the setting of established multimodal.

Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of.

Volume 350, Issue 9071, Pages (July 1997)

Volume 355, Issue 9206, Pages (March 2000)

Volume 357, Issue 9273, Pages (June 2001)

Hormonal contraceptive use and women's risk of HIV acquisition: a meta-analysis of observational studies Lauren J Ralph, MPH, Sandra I McCoy, PhD, Karen.

Volume 357, Issue 9257, Pages (March 2001)

Volume 370, Issue 9601, Pages (November 2007)

Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled,

Volume 385, Issue 9984, Pages (June 2015)

Volume 15, Issue 1, Pages (January 2014)

Effect of a bereavement support group on female adolescents' psychological health: a randomised controlled trial in South Africa Prof Tonya Renee Thurman,

Volume 376, Issue 9734, Pages (July 2010)

Year-round influenza immunisation during pregnancy in Nepal: a phase 4, randomised, placebo-controlled trial Prof Mark C Steinhoff, MD, Prof Joanne Katz,

Long-term effects of hormone replacement therapy

Volume 391, Issue 10120, Pages (February 2018)

Volume 389, Issue 10069, Pages (February 2017)

Helen Cox, Mark P Nicol The Lancet Infectious Diseases

Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard.

Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double-blind, randomised controlled trial

Volume 371, Issue 9611, Pages (February 2008)

Volume 376, Issue 9734, Pages (July 2010)

Volume 5, Issue 2, Pages e79-e86 (February 2018)

Volume 385, Issue 9977, Pages (April 2015)

Long-term effects of hormone replacement therapy

Efficacy of a Russian-backbone live attenuated influenza vaccine among young children in Bangladesh: a randomised, double-blind, placebo-controlled trial

Effect of intravenous haloperidol on the duration of delirium and coma in critically ill patients (Hope-ICU): a randomised, double-blind, placebo-controlled.

Volume 385, Issue 9966, Pages (January 2015)

Volume 15, Issue 1, Pages (January 2014)

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials David Moher, MSc, Kenneth F Schulz,

Volume 392, Issue 10147, Pages (August 2018)

Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study Dr Danielle V Clark, PhD, Hannah Kibuuka, MD, Monica.

Volume 9, Issue 10, Pages (October 2008)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised.

Misoprostol for small bowel ulcers in patients with obscure bleeding taking aspirin and non-steroidal anti-inflammatory drugs (MASTERS): a randomised,

Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled.

Volume 382, Issue 9900, Pages (October 2013)

Volume 385, Issue 9984, Pages (June 2015)

Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy.

Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled,

Volume 376, Issue 9749, Pages (October 2010)

Volume 388, Issue 10056, Pages (October 2016)

Efficacy of a Russian-backbone live attenuated influenza vaccine among young children in Bangladesh: a randomised, double-blind, placebo-controlled trial

Confessions of a journal junkie

A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled,

Effect of a bereavement support group on female adolescents' psychological health: a randomised controlled trial in South Africa Prof Tonya Renee Thurman,

Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind,

Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double-blind, randomised controlled trial

Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial Carolyn Chiswick,

Temporal associations between national outbreaks of meningococcal serogroup W and C disease in the Netherlands and England: an observational cohort study

Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial Dr.

Volume 375, Issue 9714, Pages (February 2010)

Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled,

Efficacy of a Russian-backbone live attenuated influenza vaccine among children in Senegal: a randomised, double-blind, placebo-controlled trial Dr John.

Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding,

Efficacy and safety of tribendimidine against Opisthorchis viverrini: two randomised, parallel-group, single-blind, dose-ranging, phase 2 trials Somphou.

Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled,

Effect of self-administration versus provider-administered injection of subcutaneous depot medroxyprogesterone acetate on continuation rates in Malawi:

Integrating an early childhood development programme into Bangladeshi primary health-care services: an open-label, cluster-randomised controlled trial

Preface Infectious Disease Clinics

Volume 383, Issue 9930, Pages (May 2014)

Immunogenicity and reactogenicity of ten-valent versus 13-valent pneumococcal conjugate vaccines among infants in Ho Chi Minh City, Vietnam: a randomised.

Clinic attendance and disengagement of young adults with type 1 diabetes after transition of care from paediatric to adult services (TrACeD): a randomised,

Volume 371, Issue 9611, Pages (February 2008)

An online healthy relationship tool and safety decision aid for women experiencing intimate partner violence (I-DECIDE): a randomised controlled trial

Volume 394, Issue 10193, Pages (July 2019)

Volume 18, Issue 9, Pages (September 2019)

Presentation transcript:

Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study Wilbur H Chen, MD, Kathleen M Neuzil, MD, C Rebecca Boyce, RN, Marcela F Pasetti, PhD, Mardi K Reymann, BS, Lionel Martellet, MA, Nancy Hosken, PhD, F Marc LaForce, MD, Rajeev M Dhere, PhD, Sambhaji S Pisal, PhD, Amol Chaudhari, MD, Prasad S Kulkarni, MD, Ray Borrow, PhD, Helen Findlow, PhD, Valerie Brown, MS, Megan L McDonough, MPH, Len Dally, MSc, Mark R Alderson, PhD The Lancet Infectious Diseases Volume 18, Issue 10, Pages 1088-1096 (October 2018) DOI: 10.1016/S1473-3099(18)30400-6 Copyright © 2018 Elsevier Ltd Terms and Conditions

Figure Trial profile *Ten individuals were eligible at screening but were not enrolled for the following reasons: three could not commit the time; three were unable to be contacted; two screening window expired; one unsatisfied with study payment; and one self-report of influenza. †Aluminium-phosphate adjuvanted NmCV-5 vaccine. ‡One participant was unavailable for the day 8 clinic visit but was available for the follow-up visits on days 29 and 85. The Lancet Infectious Diseases 2018 18, 1088-1096DOI: (10.1016/S1473-3099(18)30400-6) Copyright © 2018 Elsevier Ltd Terms and Conditions